Results 21 to 30 of about 4,071 (233)

Migration of a fluocinolone acetonide implant (Yutiq) to the anterior chamber and its nonurgent removal [PDF]

American Journal of Ophthalmology Case Reports, 2020
Hamidah Mahmud, Jay M. Stewart
doaj   +2 more sources

A Meta-Analysis of the Efficacy and Safety of the 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. [PDF]

Biomedicines
Background/Objectives: The fluocinolone acetonide implant (FAI) is an intravitreal corticosteroid implant designed to have a therapeutic effect lasting up to 3 years. We performed a meta-analysis to investigate the efficacy and safety of the FAI (0.19 mg,
Yeo S, Chung YR, Song JH, Bodaghi B, Touhami S.   +4 more
europepmc   +2 more sources

Real-World Clinical Outcomes After Sustained Delivery of the 0.19 mg Fluocinolone Acetonide Implant for Treatment of Diabetic Macular Edema. [PDF]

J Vitreoretin Dis
Purpose: To evaluate the real-world safety and efficacy of the 0.19 mg fluocinolone acetonide intravitreal implant for the management of diabetic macular edema (DME).
Godel S, Oncel D, Donkor R, Coney JM.
europepmc   +2 more sources

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Drug Design, Development and Therapy, 2013
Wyatt B Messenger, Robert M Beardsle, Christina J FlaxelCasey Eye Institute, Oregon Health and Science University, Portland, OR, USAAbstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser
Messenger WB, Beardsley RM, Flaxel CJ
doaj   +4 more sources

Long-Term Control of Retinal Thickness Variability and Vision Following the 0.19 mg Fluocinolone Acetonide Implant. [PDF]

J Vitreoretin Dis, 2023
Purpose: To assess the impact of retinal thickness variability (RTV) control on visual and treatment burden outcomes in patients with diabetic macular edema (DME) who received the 0.19 mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien ...
Sheth VS, Singer M, MacCumber M, Cutino A, Kasper J, Coughlin BA, Riemann CD.   +6 more
europepmc   +2 more sources

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. [PDF]

Eye (Lond), 2023
To report 5-year real-world efficacy and safety data following the treatment of chronic diabetic macular oedema (DMO) with the intravitreal 0.19 mg fluocinolone acetonide implant(ILUVIEN).
Dobler E, Mohammed BR, Chavan R, Lip PL, Mitra A, Mushtaq B.   +5 more
europepmc   +2 more sources

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments. [PDF]

J Ophthalmic Inflamm Infect
This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone implant (DEXAi)
Ferreira AM, Silva MI, Torres-Costa S, Oliveira-Ferreira C, Pedrosa AC, Figueira L, Araújo JR.   +6 more
europepmc   +2 more sources

Handshake technique for removal of fluocinolone acetonide implant from the vitreous cavity. [PDF]

BMJ Case Rep
We describe a simple technique for removing fluocinolone acetonide (FAc) implant using 25 G instrumentation in an eye with uncontrolled glaucoma. The technique involved freeing the implant from the pars plana, lifting it from the posterior pole with 25G ...
Reddy RR, Pathak Ray V, Singh DV.
europepmc   +2 more sources

Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study. [PDF]

Pharmaceutics, 2022
Diabetic macular edema (DME) is the main cause of visual impairment in diabetic patients and a chronic disease requiring long-term treatments. The fluocinolone acetonide (FAc) implant has recently been approved to treat DME in patients considered ...
Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, Vartin C, Dot C, Kodjikian L.   +8 more
europepmc   +2 more sources

The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience. [PDF]

J Ophthalmic Inflamm Infect
Background The 0.19 mg fluocinolone acetonide (FAc) implant (ILUVIEN) has been approved for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Kozak I, Gurbaxani A, Pandova M.
europepmc   +2 more sources